Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India
Leelavathy Budamakuntla,1 HV Shree-Lakshmi,1 Akshi Bansal,1 Shankar Kumar Venkatarayaraju2 1Department of Dermatology, Venerology and Leprosy, Bangalore Medical College and Research Institute, Bengaluru, Karnataka 560002, India; 2Department of Endocrinology, MS Diabetes Centre, Indiranagar, Bangalor...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e25f1439d12743b48049eca1d4ffdb28 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e25f1439d12743b48049eca1d4ffdb28 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e25f1439d12743b48049eca1d4ffdb282021-12-02T10:04:05ZSpotlight on itolizumab in the treatment of psoriasis – current perspectives from India2230-326Xhttps://doaj.org/article/e25f1439d12743b48049eca1d4ffdb282019-05-01T00:00:00Zhttps://www.dovepress.com/spotlight-on-itolizumab-in-the-treatment-of-psoriasis-current-perspect-peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XLeelavathy Budamakuntla,1 HV Shree-Lakshmi,1 Akshi Bansal,1 Shankar Kumar Venkatarayaraju2 1Department of Dermatology, Venerology and Leprosy, Bangalore Medical College and Research Institute, Bengaluru, Karnataka 560002, India; 2Department of Endocrinology, MS Diabetes Centre, Indiranagar, Bangalore 560038, India Abstract: Psoriasis is a chronic, debilitating, immune-mediated, systemic inflammatory disease affecting mainly skin, nails, and joints. Several therapeutic modalities are available depending on the severity of the disease. Long-term use of these drugs results in unwanted effects and toxicities. Recently, itolizumab, a humanized monoclonal immunoglobulin G1 antibody to CD6, has shown appreciable clinical effects and safety profile in patients with moderate-to-severe chronic plaque psoriasis. A literature search was conducted using the keywords “anti-CD6”, “psoriasis”, “phase trials”, “case series”, and “case reports”. The data from all studies conducted in India on efficacy of itolizumab in psoriasis and published before September 2017 were collected. This article provides an overview of the clinical data obtained in these published articles. Itolizumab has immunomodulatory and anti-inflammatory effects. It is efficacious and provides a good duration of remission, and hence represents a new biological agent that could be added to the therapeutic armamentarium of psoriasis. Keywords: psoriasis, biologic, monoclonal antibody, anti-CD6, Humanised IgG1 monoclonal antibody, anti CD6Budamakuntla LShree-Lakshmi HVBansal AVenkatarayaraju SKDove Medical PressarticlePsoriasisBiologicMonoclonal antibodyanti-CD6Psoriasis area and severity indexDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 9, Pp 19-27 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Psoriasis Biologic Monoclonal antibody anti-CD6 Psoriasis area and severity index Dermatology RL1-803 |
| spellingShingle |
Psoriasis Biologic Monoclonal antibody anti-CD6 Psoriasis area and severity index Dermatology RL1-803 Budamakuntla L Shree-Lakshmi HV Bansal A Venkatarayaraju SK Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India |
| description |
Leelavathy Budamakuntla,1 HV Shree-Lakshmi,1 Akshi Bansal,1 Shankar Kumar Venkatarayaraju2 1Department of Dermatology, Venerology and Leprosy, Bangalore Medical College and Research Institute, Bengaluru, Karnataka 560002, India; 2Department of Endocrinology, MS Diabetes Centre, Indiranagar, Bangalore 560038, India Abstract: Psoriasis is a chronic, debilitating, immune-mediated, systemic inflammatory disease affecting mainly skin, nails, and joints. Several therapeutic modalities are available depending on the severity of the disease. Long-term use of these drugs results in unwanted effects and toxicities. Recently, itolizumab, a humanized monoclonal immunoglobulin G1 antibody to CD6, has shown appreciable clinical effects and safety profile in patients with moderate-to-severe chronic plaque psoriasis. A literature search was conducted using the keywords “anti-CD6”, “psoriasis”, “phase trials”, “case series”, and “case reports”. The data from all studies conducted in India on efficacy of itolizumab in psoriasis and published before September 2017 were collected. This article provides an overview of the clinical data obtained in these published articles. Itolizumab has immunomodulatory and anti-inflammatory effects. It is efficacious and provides a good duration of remission, and hence represents a new biological agent that could be added to the therapeutic armamentarium of psoriasis. Keywords: psoriasis, biologic, monoclonal antibody, anti-CD6, Humanised IgG1 monoclonal antibody, anti CD6 |
| format |
article |
| author |
Budamakuntla L Shree-Lakshmi HV Bansal A Venkatarayaraju SK |
| author_facet |
Budamakuntla L Shree-Lakshmi HV Bansal A Venkatarayaraju SK |
| author_sort |
Budamakuntla L |
| title |
Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India |
| title_short |
Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India |
| title_full |
Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India |
| title_fullStr |
Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India |
| title_full_unstemmed |
Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India |
| title_sort |
spotlight on itolizumab in the treatment of psoriasis – current perspectives from india |
| publisher |
Dove Medical Press |
| publishDate |
2019 |
| url |
https://doaj.org/article/e25f1439d12743b48049eca1d4ffdb28 |
| work_keys_str_mv |
AT budamakuntlal spotlightonitolizumabinthetreatmentofpsoriasisndashcurrentperspectivesfromindia AT shreelakshmihv spotlightonitolizumabinthetreatmentofpsoriasisndashcurrentperspectivesfromindia AT bansala spotlightonitolizumabinthetreatmentofpsoriasisndashcurrentperspectivesfromindia AT venkatarayarajusk spotlightonitolizumabinthetreatmentofpsoriasisndashcurrentperspectivesfromindia |
| _version_ |
1718397731143155712 |